Screening for COPD using spyrometry



right arrow Kenneth Lin, MDBradley Watkins, MDTamara Johnson, MD, MS;Joy Anne Rodriguez, MD, MPH; and Mary B. Barton, MD, MPP  1 April 2008 | Volume 148 Issue 7 | Pages 535-543

Background: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States. Fewer than half of the estimated 24 million Americans with airflow obstruction have received a COPD diagnosis, and diagnosis often occurs in advanced stages of the disease.

Purpose: To summarize the evidence on screening for COPD using spirometry for the U.S. Preventive Services Task Force (USPSTF).

Data Sources: English-language articles identified in PubMed and the Cochrane Library through January 2007, recent systematic reviews, expert suggestions, and reference lists of retrievedarticles.

Study Selection: Explicit inclusion and exclusion criteria were used for each of the 8 key questions on benefits and harms of screening. Eligible study types varied by question.

Data Extraction: Studies were reviewed, abstracted, and rated for quality by using predefined USPSTF criteria.

Data Synthesis: Pharmacologic treatments for COPD reduce acute exacerbations in patients with severe disease. However, severe COPD is uncommon in the general U.S. population. Spirometryhas not been shown to independently increase smoking cessation rates. Potential harms from screening include false-positive results and adverse effects from subsequent unnecessary therapy.Data on the prevalence of airflow obstruction in the U.S. population were used to calculate projected outcomes from screening groups defined by age and smoking status.

Limitation: No studies provide direct evidence on health outcomes associated with screening for COPD.

Conclusion: Screening for COPD using spirometry is likely to identify a predominance of patients with mild to moderate airflowobstruction who would not experience additional health benefits if labeled as having COPD. Hundreds of patients would need toundergo spirometry to defer a single exacerbation. 

Annals 2008 148: I-46. [Full Text]  

About Ruben Roa

Medico especialista en Medicina Familiar. Magister en Epidemiologia, Economia de la Salud, Felowship en Medicina Familiar. Ex-Secretario Ejecutivo Confederación Iberoamericana de Medicina Familiar, miembro del Board de Educación Médica Continua WONCA. Senior Research at Agencia de Tecnologias Santiarias ISALUD.
This entry was posted in Annals, cribado, enfermedades cronicas, EPOC, espirometria. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s